The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection ...
Parkinson’s disease, characterized by progressive dopamine neuron loss, leads to motor deficits such as bradykinesia and rigidity, as well as nonmotor symptoms like cognitive decline and depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback